Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Biotechnology
Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.   8 March 2022
Big Pharma
Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.   7 March 2022
Americas
A seemingly small decision by the US Court of Appeals for the Federal Circuit could have a big impact on owners of design patents, explains Elizabeth Ferrill of Finnegan.   3 March 2022
Americas
The US Chamber of Commerce has warned against the proposed Covid-19 IP waiver, in its latest International IP Index, a report measuring the quality of global IP systems.   3 March 2022
Biotechnology
Harvard College and 10x Genomics have sued Nanostring Technologies, alleging that the company’s CosMx imaging platform infringes two patents covering “gene-mapping” technology.   3 March 2022
Americas
Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.   1 March 2022
Big Pharma
Japan-based Ono Pharmaceuticals has sued AstraZeneca, accusing the US pharma company of infringing patents covering an antibody used in cancer treatment.   1 March 2022
Big Pharma
Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.   1 March 2022
Big Pharma
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice.   24 February 2022
Africa
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy   24 February 2022